Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10564931			
Filing Date		2006-01-17			
First Named Inventor	Bailey	,			
Art Unit		1625			
Examiner Name	(not y	et assigned)			
Attorney Docket Numb	or	PB60402USw			

Examiner Initial*	Cite No	Patent Number Kind Issue Date Name of Patentee or Applicant Re		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1										
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n informa	tion pl	l lease click the	Add button.		Add		
			U.S.P	ATENT A	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publicat Date	ion	Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publi						d button			
				FOREIG	N PA1	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	or ,	vhere Rel	or Relevant	та
	1	03084948	wo		A1	2002-10-16	Eisai Co., Ltd.		Abstract or	nly)	×
	2	9937304	wo		A1	1999-07-29	Rhone-Poulenc Ro Pharmaceuticals In				
	3	2004101546	wo		A1	2004-11-25	Glaxo Group Limite	sd			

U.S. PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Examinor Name

Application Number		10564931		
Filing Date		2006-01-17		
First Named Inventor Bailey		,		
Art Unit		1625		
Examiner Name	(not y	et assigned)		
Attorney Docket Numb	er	PB60402USw		

If you wish	to a	dd add	ditional Foreign Patent Document citation information please click the Add button	Add	
			NON-PATENT LITERATURE DOCUMENTS	Remove	
Examiner Initials*	Cite No	(bool	de name of the author (in CAPITAL LETTERS), title of the article (when appropris k, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-iss sher, city and/or country where published.		Тв
	1				
If you wish	n to a	dd add	fitional non-patent literature document citation information please click the Add bu	utton Add	
			EXAMINER SIGNATURE		
Examiner	Signa	ture	Date Considered		
			reference considered, whether or not citation is in conformance with MPEP 809, rmance and not considered. Include copy of this form with next communication to		

1 See Kind Codes of USPTO Patent Documents at www.ISPTO.000/c of MPE 90104. 2 Enter office that issued the document, by the hor-letter code (WIPO Standard ST3.) 2 For Jungsness petant counters, the includes not not be year of the insper or the protect the sest and runner of the patent of the pat

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10564931		
Filing Date		2006-01-17		
First Named Inventor	Bailey			
Art Unit		1625		
Examiner Name	(not y	et assigned)		
Attorney Docket Numb	er	PB60402USw		

CERTIFICATION STATEMENT

Diagra con	27	CED 4	07	and 1	00 %	make the	appropriate	coloction/c	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Bonnie L. Deppenbrock/	Date (YYYY-MM-DD)	2007-09-04
Name/Print	Bonnie I. Dennenbrock	Registration Number	28 209

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1450, Alexandria, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1450, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.